Logan Coy Related postsA Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study of Topical HT-001 for Skin Toxicities Associated with Epidermal Growth Factor Receptor InhibitorSeptember 11, 2026An Open-Label, Multicenter, Phase 1b/2 Study of KRT-232 Combined with Ruxolitinib in Primary Myelofibrosis, Post-PV-MF, or Post-ET-MF with Suboptimal Response to RuxolitinibSeptember 11, 2026A Phase 2/3, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancerSeptember 11, 2026 Previous postA Phase 3, Randomized, Double-blind, Add-on Study of Navtemadlin plus Ruxolitinib vs Placebo plus Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis with Suboptimal Response to RuxolitinibNext postA Phase 1a/1b, Open-label, Dose-escalation and Dose-expansion Study of UBX-303061 in Relapsed/Refractory B-Cell Malignancies